Derma Sciences' Medihoney posted double-digit sales growth during the 1st quarter and the wound care product continues to gather fans around the world, says the company's CEO Ed Quilty. Quilty says the company added nearly 30 people to his sales and marketing staff in the first quarter of 2014 to introduce more clinicians to Medihoney. He also says the company's wound healing and scar reduction drug DSC 127 is in phase III testing and the company should have a data readout at the end of 2015. Finally, Quilty says the company is growing its presence in Europe and now has distributors in more than 20 countries.

More from Video

Jim Cramer on Intel CEO Brian Krzanich's Resignation: I Wish Him Well

Jim Cramer on Intel CEO Brian Krzanich's Resignation: I Wish Him Well

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix

Jim Cramer: Disney Has Much More Staying Power Worldwide Than Netflix

CoinShares: US Investors Should Think of Bitcoin as Digital Gold

CoinShares: US Investors Should Think of Bitcoin as Digital Gold

60 Seconds: What Are the Bank Stress Tests?

60 Seconds: What Are the Bank Stress Tests?

Video: Here's Why One Markets Pro Is Raising Cash Right Now

Video: Here's Why One Markets Pro Is Raising Cash Right Now